MetaVia Inc. Price & Performance (MTVA)

MetaVia Inc. has announced a $10 million private placement, pricing shares at $0.71 each and pre-funded warrants at $0.709. The funds will bolster working capital and support ongoing clinical trials of DA-1726, a therapy targeting obesity. The transaction is expected to close around May 12, pending customary conditions.12

Recent developments in diabetic neuropathic pain treatment include the FDA clearance of Neuralace Medical’s Axon Therapy, a non-invasive device for chronic pain, and Vertex Pharmaceuticals’ Phase II trial showing significant pain reduction with VX-548. Both advances offer hope for millions affected by diabetic nerve pain worldwide.3

Tiger Brands Ltd Sponsored ADR underwent liquidation on May 5, 2025, resulting in shareholders being credited $15.1565 per share. The payout follows a series of recent corporate actions, including reverse splits and delistings, as tracked by major brokerage platforms.4